These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38743191)

  • 1. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X; Gao X; Yang Y; Yang D; Guo Q; Li L; Liu S; Cong W; Lu S; Hou L; Wang B; Li N
    Apoptosis; 2024 Aug; 29(7-8):1161-1184. PubMed ID: 38743191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
    Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
    Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
    Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
    Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
    J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K; Yamada M; Morishita A; Ono M; Himoto T; Kobara H; Masaki T
    Biochem Pharmacol; 2024 Aug; 226():116321. PubMed ID: 38815631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
    Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
    Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 15. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
    Fu X; Liu M; Qu S; Ma J; Zhang Y; Shi T; Wen H; Yang Y; Wang S; Wang J; Nan K; Yao Y; Tian T
    J Exp Clin Cancer Res; 2018 Mar; 37(1):52. PubMed ID: 29530052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
    Wang J; Yang K; Yang X; Jin T; Tian Y; Dai C; Xu F
    Mol Carcinog; 2024 Jul; 63(7):1275-1287. PubMed ID: 38578157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
    Xie L; Li M; Liu D; Wang X; Wang P; Dai H; Yang W; Liu W; Hu X; Zhao M
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30678274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation.
    Yan S; Chen L; Zhuang H; Yang H; Yang Y; Zhang N; Liu R
    Int J Biol Sci; 2024; 20(8):3046-3060. PubMed ID: 38904018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
    Hu Q; Hu X; Zhang L; Zhao Y; Li L
    Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.